As we age, our cells accumulate genetic changes—mutations—some of which open the door to cancer. Scientists call these ...
SurvivorNet on MSN
'Mo-Rez,' a developing ovarian cancer drug, outperforms current standards with 60% response rates, offering first real hope in years
Early data show the cancer drug mocertatug rezetecan (Mo‑Rez) delivering response rates above 60% in patients with ovarian ...
Aortic aneurysms are characterized by abnormal enlargement of the aorta, the primary artery responsible for carrying blood ...
The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.
PYNNACLE enrolled heavily pretreated TP53 Y220C–mutant ovarian cancer (median four prior lines), including platinum-resistant ...
For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and ...
Finally, this thesis demonstrates that inherited predisposition, such as germline mutations in the TP53 gene, plays an important role in how treatment influences the evolution of second cancers. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results